HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) and maintained a price target of $455 for the stock.